JNJ

177.42

-0.37%↓

NVS

123.26

-0.7%↓

ABT

131.32

-1.93%↓

TMO

474.66

-1.18%↓

ISRG

433.39

-3.61%↓

JNJ

177.42

-0.37%↓

NVS

123.26

-0.7%↓

ABT

131.32

-1.93%↓

TMO

474.66

-1.18%↓

ISRG

433.39

-3.61%↓

JNJ

177.42

-0.37%↓

NVS

123.26

-0.7%↓

ABT

131.32

-1.93%↓

TMO

474.66

-1.18%↓

ISRG

433.39

-3.61%↓

JNJ

177.42

-0.37%↓

NVS

123.26

-0.7%↓

ABT

131.32

-1.93%↓

TMO

474.66

-1.18%↓

ISRG

433.39

-3.61%↓

JNJ

177.42

-0.37%↓

NVS

123.26

-0.7%↓

ABT

131.32

-1.93%↓

TMO

474.66

-1.18%↓

ISRG

433.39

-3.61%↓

Kodu・Aktsiate loetelu・Sage Therapeutics Inc

Sage Therapeutics Inc

Avatud

SektorTervishoid

8.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.69

Max

8.69

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	28. okt 2025

Uudiste sentiment

By Acuity

100%

365 / 375 Pingereas Healthcare

Sage Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. juuli 2025, 23:56 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31. juuli 2025, 23:48 UTC

Market Talk

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31. juuli 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31. juuli 2025, 23:37 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

31. juuli 2025, 23:37 UTC

Market Talk

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31. juuli 2025, 23:12 UTC

Tulu

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31. juuli 2025, 23:10 UTC

Tulu

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31. juuli 2025, 23:09 UTC

Tulu

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31. juuli 2025, 23:08 UTC

Tulu

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31. juuli 2025, 23:08 UTC

Tulu

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31. juuli 2025, 23:01 UTC

Tulu

Amazon Posts Higher Sales, Profit -- 3rd Update

31. juuli 2025, 22:08 UTC

Market Talk

Tulu

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31. juuli 2025, 22:02 UTC

Market Talk

Tulu

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31. juuli 2025, 21:57 UTC

Market Talk

Tulu

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31. juuli 2025, 21:50 UTC

Tulu

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31. juuli 2025, 21:43 UTC

Tulu

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31. juuli 2025, 21:29 UTC

Tulu

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31. juuli 2025, 21:26 UTC

Tulu

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31. juuli 2025, 21:26 UTC

Tulu

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31. juuli 2025, 21:22 UTC

Tulu

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31. juuli 2025, 21:19 UTC

Tulu

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31. juuli 2025, 21:19 UTC

Tulu

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31. juuli 2025, 21:14 UTC

Tulu

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31. juuli 2025, 21:12 UTC

Tulu

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31. juuli 2025, 21:10 UTC

Tulu

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31. juuli 2025, 21:09 UTC

Tulu

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31. juuli 2025, 21:09 UTC

Tulu

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31. juuli 2025, 21:08 UTC

Tulu

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31. juuli 2025, 21:08 UTC

Tulu

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31. juuli 2025, 21:05 UTC

Tulu

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Võrdlus sarnastega

Hinnamuutus

Sage Therapeutics Inc Prognoos

Ettevõttest Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.